BiotechTube

Placebo + Gabapentin enacarbil

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Restless Legs Syndrome (RLS)

Conditions

Restless Legs Syndrome (RLS)

Trial Timeline

Mar 30, 2017 → Jun 25, 2018

NCT ID
NCT03053427

About Placebo + Gabapentin enacarbil

Placebo + Gabapentin enacarbil is a approved stage product being developed by Astellas Pharma for Restless Legs Syndrome (RLS). The current trial status is completed. This product is registered under clinical trial identifier NCT03053427. Target conditions include Restless Legs Syndrome (RLS).

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03053427ApprovedCompleted

Competing Products

20 competing products in Restless Legs Syndrome (RLS)

See all competitors
ProductCompanyStageHype Score
Gabapentin enacarbilAstellas PharmaApproved
85
ASP8825Astellas PharmaPhase 3
77
RegniteAstellas PharmaPre-clinical
23
ASP8825 + PlaceboAstellas PharmaPhase 2
52
Apomorphine Sublingual Film + PlaceboSumitomo PharmaApproved
85
SuvorexantMerckApproved
85
CabergolinePfizerPhase 3
76
Placebo + pregabalin + pregabalinPfizerPhase 3
76
placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + PregabalinPfizerPhase 2
51
pregabalin + placebo + pramipexolePfizerPhase 3
76
placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexolPfizerPhase 3
76
cabergoline + levodopaPfizerPhase 3
76
RotigotineUCBPhase 3
74
Neupro®UCBPre-clinical
20
Rotigotine Nasal SprayUCBPhase 2
49
RotigotineUCBPhase 3
74
Levetiracetam (Keppra)UCBPhase 2
49
Rotigotine + PlaceboUCBApproved
82
RotigotineUCBPhase 2
49
RotigotineUCBPhase 3
74

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85